BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33143664)

  • 21. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
    Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
    J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma.
    Wang X; Wendel JRH; Emerson RE; Broaddus RR; Creighton CJ; Rusch DB; Buechlein A; DeMayo FJ; Lydon JP; Hawkins SM
    Oncogene; 2020 Oct; 39(40):6286-6299. PubMed ID: 32843721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
    Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
    J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
    Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
    Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
    Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
    Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
    Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel molecular profiles of endometrial cancer-new light through old windows.
    Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of a cell line from a neuroendocrine carcinoma of the endometrium and an invasion model.
    Yoshida Y; Kamitani N; Sasaki H; Kotsuji F
    Anticancer Res; 1998; 18(3A):1569-77. PubMed ID: 9673372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of "precursor escape"?
    Weng CH; Wu RC; Chen SJ; Chen HC; Tan KT; Lee YS; Huang SS; Yang LY; Wang CJ; Chou HH; Chao AS; Chao A; Lai CH
    J Mol Med (Berl); 2021 Jul; 99(7):959-966. PubMed ID: 33768299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular carcinogenesis of endometrial cancer.
    Liu FS
    Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
    Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
    Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Establishment of a new human endometrial adenocarcinoma cell line, Watanabe cells, containing estrogen receptor].
    Satoh T; Nishida M; Oki A; Tsunoda H; Kasahara K; Kubo T
    Hum Cell; 1995 Dec; 8(4):195-201. PubMed ID: 8721091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma.
    Isaka K; Nishi H; Sagawa Y; Nakada T; Osakabe Y; Serizawa H; Ebihara Y; Takayama M
    Cancer Genet Cytogenet; 2003 Feb; 141(1):20-5. PubMed ID: 12581894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
    Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
    Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
    Guan B; Wang TL; Shih IeM
    Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clear cell carcinoma of the endometrium confined to atrophic endometrial polyp--case report].
    Simon SK; Bolanca IK; Sentija K; Zovko G; Podgajski M; Valetić J; Skrtić A
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():143-8. PubMed ID: 23126043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.